A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension

计划入组 231 人 · 首次发布于 2021 年 5 月 10 日

A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

计划入组 32 人 · 首次发布于 2026 年 1 月 22 日

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

计划入组 42 人 · 首次发布于 2025 年 4 月 9 日

Efimosfermin alfa

GSK Acquires Efimosfermin for $1.2 Billion to Target Steatotic Liver Disease

GSK Acquires Boston Pharmaceuticals' Efimosfermin for Liver Disease in $2 Billion Deal

GSK Acquires Efimosfermin Alfa from Boston Pharmaceuticals in $2 Billion Deal for Liver Disease Treatment